Key facts
- It has raised $670K across 1 recorded rounds; the latest was Seed Round ($670K) in Oct 2024.
- ATED Therapeutics has filed 1 Form D with the SEC, most recently Apr 2026 ($670K sold to 13 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for ATED Therapeutics
Funding rounds
1 roundsAbout ATED Therapeutics
Developer of diagnostic tests intended for neurodegenerative diseases. The company developed a new, rapid, simple, transfer RNA-based diagnostic test for parkinson's disease, which also provides a quantitative measurement of the effectiveness of deep brain stimulation, enabling patients to get early intervention and, importantly, tracks disease progression.
- Sector
- Healthcare
- HQ
- Greenwich, CT, United States
- Founded
- 2022
- Website
- atedtherapeutics.org/
- Ownership
- Privately Held (backing)
ATED Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ATED Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ATED Therapeutics in its N-PORT filings yet. We sweep new filings monthly.